论文部分内容阅读
绿脓杆菌是临床上的主要病原菌,对很多药物显示低敏感性.尽管绿脓杆菌对抗生素的固有耐药性尚不清楚,但这可能是由于药物对外膜的低通透性所致.在治疗绿脓杆菌感染期间,当仅仅使用抗假单胞菌β-内酰胺类抗生素时,就发展了对这类抗生素的耐药性.此耐药性由归因于去阻遏的前诱导性高水平β-内酰胺酶(染色体编码β-内酰胺酶)所致,正如在头孢他啶耐药菌中所看到的那样.并且,碳青霉烯耐药性的产生是由于缺乏外膜蛋白D2,从而降低了此类抗生素对外膜通透性所引起的.Satake等(1991)报道这两种耐药机制,不仅在各种临床分离绿脓杆菌中单独存在,而且还共同存在于同一株菌中.
Pseudomonas aeruginosa is the major clinical pathogen and shows low sensitivity to many drugs.Although the inherent resistance of Pseudomonas aeruginosa to antibiotics is not clear, this may be due to the drug’s low permeability to the outer membrane. During treatment of Pseudomonas aeruginosa, resistance to such antibiotics develops when anti-Pseudomonas beta-lactam antibiotics are used alone.Antibiotic resistance is caused by pre-induction due to derepression The level of beta-lactamase (chromosomally encoded beta-lactamase) results, as seen in ceftazidime resistant bacteria, and the development of carbapenem resistance is due to the lack of outer membrane proteins D2, Thus reducing the antibacterial permeability caused by the outer membrane.Satake et al (1991) reported that these two resistance mechanisms, not only in a variety of clinically isolated Pseudomonas aeruginosa alone, but also co-exist in the same strain .